Compass Therapeutics, Inc.
CMPX Nasdaq
SEC CIK 1738021
Follow Compass Therapeutics
Weekly email: filings, results
Net income
−$27.2M
−90.6% vs same quarter last year
EPS, diluted
−$0.15
−87.5% vs same quarter last year
Operating cash flow
−$16.3M
−50.4% vs same quarter last year
Operating income
−$28.8M
−82.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$66.5M |
| FY24 | $850K | −$49.4M |
| FY23 | $0 | −$42.5M |
| FY22 | - | −$39.2M |
| FY21 | - | −$82.2M |
| FY20 | - | −$29.5M |
| FY19 | - | −$34.7M |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$49.2M |
| FY24 | −$44.9M |
| FY23 | −$40.6M |
| FY22 | −$34.3M |
| FY21 | −$21.2M |
| FY20 | −$26.9M |
| FY19 | −$32.2M |
| FY18 | - |